Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | USP2 | O75604 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.71 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.71 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.71 |
| ▸ | GSTP1 | P09211 | 3/20 | 0.50 |
| ▸ | GSTM2 | P28161 | 3/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | RECQL | P46063 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242737 | 0.88 | MEN1 (0.70) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL5294666 | 0.88 | MEN1 (0.70) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL5341701 | 0.87 | MEN1 (0.68) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL3502339 | 0.85 | MEN1 (0.77) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL3500025 | 0.85 | MEN1 (0.97) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL6391113 | 0.84 | MEN1 (0.75) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL3505138 | 0.83 | MEN1 (1.00) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL8159616 | 0.83 | KMT2A (0.70) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL5329963 | 0.83 | MAPT (0.64) | MEN1KMT2AUSP2POLBTNNI3 | |
| SCHEMBL5300515 | 0.83 | POLB (0.65) | MEN1KMT2AUSP2POLBTNNI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TENT4B, IRF3, MAVS | MEN1 4597/4885KMT2A 1674/4885USP2 1795/4885 |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | MEN1 3562/4885KMT2A 1303/4885USP2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.